BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3277732)

  • 21. An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.
    Ewen C; Perera A; Hendry JH; McAuliffe CA; Sharma H; Fox BW
    Cancer Chemother Pharmacol; 1988; 22(3):241-5. PubMed ID: 3044632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
    Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
    Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
    Ueda T; Yasumasu T; Uozumi J
    J Toxicol Sci; 1991 Aug; 16(3):101-9. PubMed ID: 1942134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
    Jacobs S; McCully CL; Murphy RF; Bacher J; Balis FM; Fox E
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):817-24. PubMed ID: 19662415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
    Kizu R; Higashi S; Kidani Y; Miyazaki M
    Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
    Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
    J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
    Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of cisplatin derivatives -3H-cis-1,2-diaminocyclohexanedichloroplatinum (II) and 3H-cis-1,2-diaminocyclohexanemalonatoplatinum (II) in BDF1 mice.
    Oswald CB; Wyrick SD; Chaney SG; Shrewsbury RO; Hall IH
    Res Commun Chem Pathol Pharmacol; 1989 Apr; 64(1):41-58. PubMed ID: 2749002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
    Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
    J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological approach to the platinum compounds].
    Sasaki Y
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of carboplatin].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
    Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
    Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
    Owens SE; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer JC; McAuliffe CA; Crowther D
    Cancer Chemother Pharmacol; 1985; 14(3):253-7. PubMed ID: 3888431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacokinetics of carboplatin (CBDCA) and tissue concentration of platinum in gynecologic organs].
    Fujiwara K; Miyagi Y; Hayase R; Yoshinouchi M; Kobashi Y; Kohno I; Sekiba K
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1943-8. PubMed ID: 3289504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
    Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
    Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine.
    Binks SP; Dobrota M
    Biochem Pharmacol; 1990 Sep; 40(6):1329-36. PubMed ID: 2206139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
    Holzer AK; Manorek GH; Howell SB
    Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The disposition of carboplatin in ovarian cancer patients.
    Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
    Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.